Evidence map›Paper›PMID 30396359›Full record

ArticleJournal of neuroinflammation2018

TLR4 inhibitor TAK-242 attenuates the adverse neural effects of diet-induced obesity.

V Alexandra Moser, Mariana F Uchoa, Christian J Pike

Open access · goldAbstract read
In one paragraph

Article in Journal of neuroinflammation, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 64 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Aqueous Extracts ofPlants (Basel, Switzerland) · 2024
    Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Genes & diseases · 2023
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

V Alexandra MoserNeuroscience Graduate Program, University of Southern California, 3641 Watt Way, HNB 120, Los Angeles, CA, 90089, USA.
Mariana F UchoaNeuroscience Graduate Program, University of Southern California, 3641 Watt Way, HNB 120, Los Angeles, CA, 90089, USA.
Christian J PikeNeuroscience Graduate Program, University of Southern California, 3641 Watt Way, HNB 120, Los Angeles, CA, 90089, USA. cjpike@usc.edu.ORCID http://orcid.org/0000-0003-4577-7668
University of Southern California · US

Funding

Timing of Menopausal Hormone Therapy across Perimenopause to Menopause Transition: Neuroimmune System in BrainP01AG026572 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI ROBERTA EILEEN BRINTON · 2006 to 2026
$53.7M
Amyloid and inflammation: modulation by apoE, gender, air pollution, and drugsRF1AG051521 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI FINCH, CALEB E · 2015 to 2015
$3.0M
Alzheimer's Association SAGA-17-419-408NIA NIH HHS AG051521NIA NIH HHS AG26572NIA NIH HHS P01 AG026572NIA NIH HHS RF1 AG051521
6 · The paper itself

Abstract

backgroundObesity exerts negative effects on brain health, including decreased neurogenesis, impaired learning and memory, and increased risk for Alzheimer's disease and related dementias. Because obesity promotes glial activation, chronic neuroinflammation, and neural injury, microglia are implicated in the deleterious effects of obesity. One pathway that is particularly important in mediating the effects of obesity in peripheral tissues is toll-like receptor 4 (TLR4) signaling. The potential contribution of TLR4 pathways in mediating adverse neural outcomes of obesity has not been well addressed. To investigate this possibility, we examined how pharmacological inhibition of TLR4 affects the peripheral and neural outcomes of diet-induced obesity.

methodsMale C57BL6/J mice were maintained on either a control or high-fat diet for 12 weeks in the presence or absence of the specific TLR4 signaling inhibitor TAK-242. Outcomes examined included metabolic indices, a range of behavioral assessments, microglial activation, systemic and neuroinflammation, and neural health endpoints.

resultsPeripherally, TAK-242 treatment was associated with partial inhibition of inflammation in the adipose tissue but exerted no significant effects on body weight, adiposity, and a range of metabolic measures. In the brain, obese mice treated with TAK-242 exhibited a significant reduction in microglial activation, improved levels of neurogenesis, and inhibition of Alzheimer-related amyloidogenic pathways. High-fat diet and TAK-242 were associated with only very modest effects on a range of behavioral measures.

conclusionsThese results demonstrate a significant protective effect of TLR4 inhibition on neural consequences of obesity, findings that further define the role of microglia in obesity-mediated outcomes and identify a strategy for improving brain health in obese individuals.

Indexed as

AdiposityAnimalsAnti-Obesity AgentsBlood GlucoseBody CompositionBody WeightCalcium-Binding ProteinsCholesterolConditioning, ClassicalDiet, High-FatDisease Models, AnimalExploratory BehaviorFearMaleMaze LearningMiceAif1 protein, mouseAnti-Obesity AgentsBlood GlucoseCalcium-Binding ProteinsCholesterolethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylateMicrofilament ProteinsSulfonamidesTriglyceridesAdiposityAlzheimer’s diseaseInflammationMicrogliaObesityToll-like receptor 4

Identifiers

PMID30396359
PMCPMC6217784
OpenAlexW2900236410

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.